Patient Guide to Lutetium-177 PSMA Therapy

Lutetium-177 (177Lu) PSMA therapy is a targeted treatment for prostate cancer. This therapy uses radioactive Lutetium-177 attached to a molecule that specifically targets prostate cancer cells expressing PSMA (Prostate-Specific Membrane Antigen). This allows the radiation to be delivered precisely to cancer cells while minimising effects on healthy tissue.

The treatment is administered through an infusion, during which your vital signs will be carefully monitored. Following the treatment, you may undergo Whole Body Scans to assess the efficacy of the therapy.

During Your Treatment

Treatment Day:

• Vital signs monitoring throughout infusion
• Whole-Body Scans after treatment
• Special care instructions will be provided

Essential Care:

• Drink at least 1 litre of fluid daily (unless advised otherwise)
• Take all prescribed medications as directed

Safety Precautions

Personal Hygiene:

• Maintain daily personal hygiene
• Shower regularly
• Wash hands thoroughly after toilet use
• Clean any spills of bodily fluids immediately
• Wash soiled linen separately from family laundry

For the First 2 Days:

• Avoid crowded places
• Sleep separately from adults
• Avoid intimacy
• Maintain arm's length distance from children under 12 and pregnant women
• Sit while urinating (including men)
• Double flush toilet after use

Extended Precautions:

• Sleep separately from pregnant women and children under 12 for 2 days
• Avoid public transport journeys over 3 hours for 3 days
• Avoid impregnating partner for 6 months

Travel Information

Over the next four weeks, you must carry your discharge note when travelling as you may trigger radiation detection devices at airports, public transportation facilities, and other security checkpoints due to low radiation levels. If you plan to travel overseas shortly after treatment, please request a travel memo from your doctor. You may return to work as soon as you feel well enough.

Medical Attention

Please seek immediate medical attention if you experience a fever of 38°C or above, persistent vomiting, or any prolonged symptoms that concern you.

Contact Information

If you need to clarify on any of the above conditions, you can contact your primary physician through the operator or ward nurse clinician in-charge.

During office hours, you can reach the Department of Nuclear Medicine and Molecular Imaging at 6326 5357 or the National Cancer Centre at 6438 8000. For after-hours care, please contact the Hospital’s General Enquiry Hotline at 6222 3322.

Follow-Up Care

Your follow-up care will include regular blood tests to monitor your blood count, kidney and liver function, and PSA levels to assess your response to treatment. The Department of Nuclear Medicine and Molecular Imaging will schedule your follow-up appointments.

To change any appointments, you can:

• Contact SGH appointment hotline: 6321 4377
• Send an email to: appointments@sgh.com.sg
• Call the Department of Nuclear Medicine directly: 6326 5357

Our patient information leaflet is available for download: 177Lu-PSMA Therapy (Eng).pdf